Clinical Trials
Artificial Intelligence – Giving Clinical Trial A Facelift
Across the past so many years, there have been pharmaceutical companies that have been integrating artificial intelligence steadily into many elements of clinical development. The effect that artificial intelligence has today is indeed being felt right from the bench...
Clinical Trials
New Data Shows Gazyva’s Superiority in Lupus Nephritis
The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination with standard therapy for treating active lupus nephritis (LN). The trial shows a compelling...
Clinical Trials
EYLEA HD® Phase 3 Trial Yields Promising Results
Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in patients with retinal vein occlusion (RVO). The results were presented during the Angiogenesis 2025 annual...
Clinical Trials
Pfizer’s BRAFTOVI Improves Survival in Phase 3 Trial
Pfizer has announced groundbreaking results from the Phase 3 BREAKWATER trial, showcasing the effectiveness of its BRAFTOVI® (encorafenib) combination regimen in the treatment of metastatic colorectal cancer (mCRC) with the BRAF V600E mutation. The trial highlights significant improvements in...
Clinical Trials
VerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the EFS with unprecedented yields
EVerZom, a biopharmaceutical company developing  exosome based biodrugs, announces that it has reached a key milestone in its development with the production of a first exosome GMP batch in a 10L bioreactor with unprecedented yields. Regulatory validation of the technology was carried out in GMP clean rooms of...
Clinical Trials
New Endometrial Cancer Therapy Phase-II Trial Shows Promise
The most recent trial of a new antibody drug that goes on to deliver potent chemotherapy that too directly to the cancer cells for patients with advanced or recurrent endometrial cancer has gone a notch up to be studied...
Clinical Trials
Duality Looks Out For Hong Kong IPO To Finance ADC Trials
Duality Biotherapeutics from China has gone ahead and filed paperwork as far as a Hong Kong IPO is concerned, thereby looking out for an undisclosed sum so as to power a broad pipeline when it comes to antibody conjugates...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
